Dr. igor splawski appointed as chief scientific officer of yarrow biotechnology

New york--(business wire)--yarrow biotechnology, inc. (“yarrow”), an rtw investments, lp (“rtw”) -incubated company developing nucleic acid therapeutics and other modalities for severe, genetically defined diseases including those of the central nervous system (“cns”), today announced the appointment of dr. igor splawski as chief scientific officer. dr. splawski was previously the chief scientific officer and a member of the executive board of curevac (nasdaq: cvac), where he led a team of 150.
CVAC Ratings Summary
CVAC Quant Ranking